Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

The lysosomal storage disorders (LSD) are a group of severe multiple pathology disorders characterized by enzyme deficiencies which cause the lysosomal accumulation of undegraded or partially degraded macromolecules. Enzyme replacement therapy (ERT) has been developed as a therapy for LSD patients. However, immune responses to ERT have been reported in some individuals from LSD animal model and LSD human patient studies. Antibodies can have adverse effects during ERT, which include hypersensitivity/anaphylactic reactions, enzyme inactivation, altered targeting, and increased enzyme turnover. The monitoring of antibody production during replacement therapy is an important consideration for patient management, as high-titer antibodies can affect the safety and efficacy of the therapy.

[1]  C. Bond,et al.  Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats. , 1999, Molecular genetics and metabolism.

[2]  M. Rosenberg,et al.  Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. , 1999, Blood.

[3]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[4]  D. Brooks,et al.  Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model. , 1998, Biochimica et biophysica acta.

[5]  T. Stockley,et al.  Suppression of immunological response against a transgene product delivered from microencapsulated cells. , 1998, Human gene therapy.

[6]  E. Beutler.  8 Enzyme replacement therapy for Gaucher's disease , 1997 .

[7]  R. Brady.  1 Gaucher's disease: past, present and future , 1997 .

[8]  R. Brady,et al.  Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. , 1997, Pediatrics.

[9]  I. Mellman,et al.  Delivery of B Cell Receptor–internalized Antigen to Endosomes and Class II Vesicles , 1997, The Journal of experimental medicine.

[10]  D. Brooks,et al.  Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. , 1997, Biochimica et biophysica acta.

[11]  G. Grabowski,et al.  Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. , 1997, Blood.

[12]  W. Sly,et al.  Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. , 1997, The Journal of clinical investigation.

[13]  F. Jirik,et al.  Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. , 1997, Human molecular genetics.

[14]  J. Hopwood,et al.  Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. , 1997, The Journal of clinical investigation.

[15]  A. Schmidtchen,et al.  Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. , 1996, Biochemical and molecular medicine.

[16]  D. Brooks,et al.  Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. , 1996, The Journal of clinical investigation.

[17]  J. Dambrosia,et al.  Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. , 1995, Pediatrics.

[18]  M. Kay,et al.  Immunomodulation to enhance gene therapy , 1995, Nature Network Boston.

[19]  M. Mcentee,et al.  Enzyme replacement in a canine model of Hurler syndrome. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Sly,et al.  Enzyme replacement therapy for murine mucopolysaccharidosis type VII. , 1994, The Journal of clinical investigation.

[21]  I. Mellman,et al.  Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes , 1994, Nature.

[22]  G. Grabowski,et al.  Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. , 1993, Blood.

[23]  J. Dambrosia,et al.  Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease. , 1992, The Journal of pediatrics.

[24]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[25]  H. Hers.  INBORN LYSOSOMAL DISEASES. , 1965, Gastroenterology.

[26]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[27]  Hers Hg,et al.  The genetic pathology of lysosomes. , 1970 .

[28]  C. Duve,et al.  Functions of lysosomes. , 1966, Annual review of physiology.

[29]  C. Deduve.  FROM CYTASES TO LYSOSOMES. , 1964, Federation proceedings.

[30]  H. Hers.  α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease) , 1963 .